| Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study. | |
| | |
MedLine Citation:
|
PMID: 22265068 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) to insulin detemir (IDet) in patients with type 2 diabetes in the setting of Chinese secondary and tertiary hospitals. METHODS: A published and validated computer simulation model of diabetes (the Center for Outcomes Research model) was used to make the long-term (30 years) projection of health economic outcomes. Patient demographic information and clinical end points were derived from a subgroup analysis of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation (PREDICTIVE) study. Baseline risk factors and racial characteristic data were obtained from Chinese cohort studies. The diabetes management and complications costs were obtained from Chinese published data and adjusted to 2010 values by using the Chinese consumer price index. An annual discounting rate of 3% was used for both health and cost outcomes, and one-way sensitivities analysis was performed, which illustrated that the results were robust. RESULTS: Conversion to IDet from IGla was projected to improve patient life expectancy by 0.06 year and 0.48 quality-adjusted life-years. Drug costs and management costs of diabetes mellitus were increased by US$368 (US$17,466 vs. US$17,097) and US$31 (US$5464 vs. US$5433), respectively. However, the costs of complications, including cerebrovascular disease, renal complications, ulcer/amputation/neuropathy, eye complications, and hypoglycemia events, were reduced by US$819 (US$21,294 vs. US$22,114), resulting in a total direct medical cost saving of US$420 when converting to IDet. CONCLUSIONS: Conversion to IDet from an IGla regimen improved life expectancy and was a cost-saving treatment approach in a Chinese setting. |
| | |
Authors:
|
Li Yang; Torsten Christensen; Fengyu Sun; Jinghua Chang |
Related Documents
:
|
17689128 - Serum ghrelin levels but not gh, igf-1 and igfbp-3 levels are altered in patients with ... 6240148 - The presence of normal levels of serum immunoreactive insulin-like growth factor 2 (igf... 8671178 - Oxytocin affects the release of steroids, insulin-like growth factor-i, prostaglandin f... 11992058 - A comparison of multiple urine markers for interstitial cystitis. 22315308 - Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a... 8968688 - Prevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes cent... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Volume: 15 ISSN: 1524-4733 ISO Abbreviation: Value Health Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-01-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883818 Medline TA: Value Health Country: United States |
Other Details:
|
Languages: eng Pagination: S56-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Health Policy and Management, School of Public Health, Peking University, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-effectiveness of various tuberculosis control strategies in Thailand.
Next Document: A multilevel analysis of regional and individual effects on methadone maintenance treatment in taiwa...